Related Experiment Video

Updated: Oct 23, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

New targets in endocrine-resistant hormone receptor-positive breast cancer

Laura C Kennedy1, Ingrid A Mayer1

  • 1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Clinical Advances in Hematology & Oncology : H&O
|August 19, 2021
PubMed

Insights

New treatments are needed for advanced hormone receptor-positive breast cancer that resists endocrine therapy. This review covers current targeted therapies and emerging agents for this challenging disease.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Endocrine-based treatments are foundational for advanced hormone receptor-positive (HR+) breast cancer.
  • Therapeutic resistance to endocrine therapy is a significant clinical challenge in advanced HR+ breast cancer.
  • Active research is focused on developing novel strategies to overcome endocrine resistance.

Purpose of the Study:

  • To review current standard-of-care targeted therapies for advanced HR+ breast cancer.
  • To discuss investigational agents with potential for treating endocrine-resistant advanced HR+ breast cancer.
  • To provide an overview of therapeutic options for managing advanced HR+ breast cancer.

Main Methods:

  • Literature review of targeted therapies for advanced hormone receptor-positive breast cancer.
  • Analysis of current standard-of-care agents.
  • Discussion of emerging therapeutic agents under investigation.

Main Results:

  • Established targeted therapies form the current standard of care for advanced HR+ breast cancer.
  • Several novel agents are under investigation for their efficacy in endocrine-resistant disease.
  • The landscape of treatment is evolving with the introduction of new therapeutic strategies.

Conclusions:

  • Targeted therapies are crucial in managing advanced HR+ breast cancer.
  • Ongoing research into new agents is vital for addressing endocrine resistance.
  • A combination of standard and investigational therapies holds promise for improved patient outcomes.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.1K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.2K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K